Replix锐璞美股

Replix锐璞美股

Replix锐璞美股生物医药研究团队,专注于发掘不为投资人所知的优质创新型医药公司。团队具备深厚的生物医药、金融和财务背景。坚持严谨的基本面分析,挖掘出了众多创新性足,其产品能改变病种治疗体系的公司。年复合收益超过45%。 公司网址:https://replixbio.com/; 微信公众号:Replixtrading; 商务合作以及技术咨询微信:replixtrading

Replix锐璞美股回复的提问

ACOR, ACST,NBRV 去年各种问题已经成Penny stock,未来怎么看这三家的公司业绩和股价发展? 是否有其他潜力医药小盘推荐的?

他的全部讨论

$Five Prime(FPRX)$ 被收购! Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Ther...

$Ovid Therapeutics(OVID)$ 首付款拿了2个亿 entered into a Royalty, License and Termination Agreement (the “New Agreement”) with Takeda Pharmaceutical Company Limited (“Takeda”), relating to the prior License and Collaboration Agreement that the Company entered into with T...

$Passage Bio(PASG)$ $PASG$ Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights - On track to initiate three Phase 1/2 clinical programs in the first half of 2021: PBGM01 for GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia w...

$Satsuma制药(STSA)$ STSA Satsuma Pharmaceuticals Announces $80 Million Private Placement Financing 盘前大幅上涨 $基因进化ETF-ARK(ARKG)$ $特斯拉(TSLA)$

$Phio Pharmaceuticals(PHIO)$ PHIO PHARMACEUTICALS AND AGONOX, INC. ANNOUNCE COLLABORATION ON CLINICAL DEVELOPMENT OF NOVEL T CELL-BASED CANCER IMMUNOTHERAPIES Under the terms of the collaboration agreement, AgonOx will receive financial support for the clinical trial from Ph...

$Arvinas(ARVN)$ Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Cash, Cash Equivalents and Marketable Securities Position: As of December 31, 2020, cash, cash equivalents and marketable securities were $688.5 million Anticipa...

$逻辑器件(LOGC)$ 管理层以7.8的价格买入不少

$Cassava Sciences(SAVA)$ SAVA Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease. FDA has agreed that the completed Phase 2 program, together with an upcoming and well-defined Phase 3...

$Immunovant(IMVT)$ @美股医药Z博士 IMVT是一家做格氏病的小型生物药企,年初至今已经跌的超过一半,主要原因是公司主动暂停了公司唯一的管线的临床研究。因为是唯一药物,对公司影响巨大,稍有风吹草动可能都会剧烈影响股价。请参考我们的简评:网页链接。 $基...

欧盟向Moderna额外采购1.5亿剂疫苗,使总采购量达到3.1亿剂 ---150 million doses scheduled to be delivered in Q3 and Q4, 2021 ---With this new purchase, total of 310 million doses ordered by the to date for delivery in 2021 ---Contract includes an option to purchase an additiona...

Moderna Provides U.S. COVID-19 Vaccine Supply Update Company has supplied 45.4 million doses of Moderna COVID-19 Vaccine to U.S. Government to date The CDC communicated that approximately 25.5 million doses of the Moderna COVID-19 Vaccine have been administered in the U.S. A...

$Atreca(BCEL)$ wow,飙起来

$bluebird bio(BLUE)$ 蓝鸟生物因毒副作用而暂停HGB-206和HGB-210的临床 bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)

$Atreca(BCEL)$ 这家公司曾入选最猛生物科技公司,网站非常业余,披露的临床信息也很有限,但背后金主阵容豪华。为何大机构青睐这家小药企?请查看:网页链接$基因进化ETF-ARK(ARKG)$ $Moderna(MRNA)$ @淘沙见金 @飞冲天 @药师老庙 @美股医药Z博士 @Efficac...

谢谢您啦,牛牛牛!//@逆向思维静待花开:感谢锐璞团队带我飞,祝锐璞收益节节高升,牛年账户全牛股,🐮🐮🐮

涨了点